Temporal trends in critical care burden and outcomes of Andes virus-associated hantavirus cardiopulmonary syndrome: a national Chilean cohort

Intensive Care MedPublished Retrospective cohort study

Authors' conclusion

HCPS caused by Andes virus remains associated with high in-hospital mortality and substantial amounts of respiratory support, particularly MV and ECMO. Moreover, the COVID-19 pandemic was associated with a significant increase in HCPS mortality.

Study context

Population
Patients admitted with Andes virus hantavirus cardiopulmonary syndrome (HCPS) in 31 Chilean hospitals, 2019–2024
Participants
215 patients · 31 hospitals
Exposure
Patients stratified by maximal respiratory support: none, non-invasive ventilation (NIV), invasive mechanical ventilation (MV) or extracorporeal membrane oxygenation (ECMO); pre-COVID-19, pandemic and post-pandemic periods
Outcome
Hospital LOS and in-hospital mortality
Methodological detailsnational, multicentre, administrative database (Diagnosis-Related Groups)
  • National
  • Multicentre
  • Administrative database (Diagnosis-Related Groups)

Main finding

As reported in the abstract

Hospital LOS and in-hospital mortality (whole cohort)

Hospital length of stay (LOS), days

8

3–15

In-hospital mortality

20.5%

Observational data: associations, not effects.

Further findings

In-hospital mortality by period

aOR (CI)P value
Pandemic periodIndependently associated2.73 (1.06–7.63)P = 0.045
OutcomeNIVMVECMO
Case fatality rate by maximal respiratory support— not stated in the abstract29.6%32.9%
Respiratory support use among 148 patients requiring support14.2%36.5%49.3%

— not stated in the abstract

Original publication

Temporal trends in critical care burden and outcomes of Andes virus-associated hantavirus cardiopulmonary syndrome: a national Chilean cohort. Intensive Care Med. Published 2 September 2026. doi:10.1007/s00134-026-08599-9

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.